Affibody CEO describes three-year growth plan

Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development progress for the company's novel class of antibody mimetics, which he says have superior characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. They also discuss Affibody's collaborative business model and current partnerships in various geographies, including an important arrangement for the business with Daiichi Sankyo in Japan.

[video src="https://www.youtube.com/embed/FD9Fw-5d3U0"]

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: David Bejker – CEO, Affibody AB